

# Nesrin Mogulkoc

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8076781/publications.pdf>

Version: 2024-02-01

58  
papers

1,682  
citations

516710

16  
h-index

345221

36  
g-index

58  
all docs

58  
docs citations

58  
times ranked

1782  
citing authors

#	ARTICLE	IF	CITATIONS
1	Pulmonary Function in Idiopathic Pulmonary Fibrosis and Referral for Lung Transplantation. American Journal of Respiratory and Critical Care Medicine, 2001, 164, 103-108.	5.6	222
2	Comparison of echocardiographic markers of right ventricular function in determining prognosis in chronic pulmonary disease. Journal of the American Society of Echocardiography, 2002, 15, 633-639.	2.8	186
3	Intracardiac Thrombus in Behçet's Disease. Chest, 2000, 118, 479-487.	0.8	184
4	Pulmonary Langerhansâ€™ Cell Histiocytosis. Chest, 1999, 115, 1452-1455.	0.8	145
5	Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study. Lancet Respiratory Medicine, the, 2019, 7, 780-790.	10.7	139
6	Acute Purulent Exacerbation of Chronic Obstructive Pulmonary Disease and Chlamydia pneumoniae Infection. American Journal of Respiratory and Critical Care Medicine, 1999, 160, 349-353.	5.6	117
7	Resequencing Study Confirms That Host Defense and Cell Senescence Gene Variants Contribute to the Risk of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 199-208.	5.6	90
8	Evaluation of CMV viral load using TaqMan CMV quantitative PCR and comparison with CMV Antigenemia in heart and lung transplant recipients. Transplantation, 2001, 71, 1609-1615.	1.0	85
9	Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers?. Lancet Respiratory Medicine, the, 2017, 5, 591-598.	10.7	71
10	The effect of inhaled corticosteroids on bronchoalveolar lavage cells and IL-8 levels in stable COPD patients. Respiratory Medicine, 2005, 99, 1494-1500.	2.9	54
11	The European MultiPartner IPF registry (EMPIRE): validating long-term prognostic factors in idiopathic pulmonary fibrosis. Respiratory Research, 2020, 21, 11.	3.6	42
12	High dose rate endobronchial brachytherapy in combination with external beam radiotherapy for stage III non-small cell lung cancer. Lung Cancer, 2001, 34, 253-259.	2.0	40
13	High dose rate endobronchial brachytherapy in the management of lung cancer: Response and toxicity evaluation in 158 patients. Lung Cancer, 2008, 62, 326-333.	2.0	40
14	Serial CT analysis in idiopathic pulmonary fibrosis: comparison of visual features that determine patient outcome. Thorax, 2020, 75, 648-654.	5.6	26
15	The DIAMORFOSIS (DIagnosis and Management Of lung canceR and FibrOSIS) survey: international survey and call for consensus. ERJ Open Research, 2021, 7, 00529-2020.	2.6	22
16	Effects of Nintedanib on Quantitative Lung Fibrosis Score in Idiopathic Pulmonary Fibrosis. Open Respiratory Medicine Journal, 2020, 14, 22-31.	0.4	21
17	Impact of lung morphology on clinical outcomes with riociguat in patients with pulmonary hypertension and idiopathic interstitial pneumonia: A post hoc subgroup analysis of the RISE-IIP study. Journal of Heart and Lung Transplantation, 2021, 40, 494-503.	0.6	20
18	Patient-reported outcomes and patient-reported outcome measures in interstitial lung disease: where to go from here?. European Respiratory Review, 2021, 30, 210026.	7.1	17

#	ARTICLE	IF	CITATIONS
19	The association between white blood cell count and outcomes in patients with idiopathic pulmonary fibrosis. <i>Respiratory Medicine</i> , 2020, 170, 106068.	2.9	16
20	Endobronchial Metastasis From Osteosarcoma of Bone. <i>Chest</i> , 1999, 116, 1811-1814.	0.8	15
21	B-cell isotype control in atopy and asthma assessed with cDNA array technology. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2001, 280, L627-L637.	2.9	13
22	A rare tumor of the lung: Pulmonary sclerosing hemangioma (pneumocytoma). <i>Respiratory Medicine</i> , 2013, 107, 448-450.	2.9	13
23	Anticoagulant Use and Bleeding Risk in Central European Patients with Idiopathic Pulmonary Fibrosis (IPF) Treated with Antifibrotic Therapy: Real-World Data from EMPIRE. <i>Drug Safety</i> , 2020, 43, 971-980.	3.2	13
24	Right ventricular free wall longitudinal speckle tracking strain in patients with pulmonary arterial hypertension under specific treatment. <i>Echocardiography</i> , 2017, 34, 530-536.	0.9	12
25	Dynamic Computed Tomography in Solitary Pulmonary Nodules. <i>Journal of Computer Assisted Tomography</i> , 2008, 32, 222-227.	0.9	10
26	Phase 2B Study of Inhaled RVT-1601 for Chronic Cough in Idiopathic Pulmonary Fibrosis: A Multicenter, Randomized, Placebo-controlled Study (SCENIC Trial). <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 1084-1092.	5.6	10
27	An Unusual Presentation of Anti-Jo-1 Syndrome, Mimicking Lung Metastases, With Massive Pleural and Pericardial Effusions. <i>Journal of Clinical Rheumatology</i> , 2006, 12, 90-92.	0.9	9
28	Mortality in combined pulmonary fibrosis and emphysema patients is determined by the sum of pulmonary fibrosis and emphysema. <i>ERJ Open Research</i> , 2021, 7, 00316-2021.	2.6	6
29	Pleuroparenchymal fibroelastosis in idiopathic pulmonary fibrosis: Survival analysis using visual and computer-based computed tomography assessment. <i>EClinicalMedicine</i> , 2021, 38, 101009.	7.1	6
30	Effects of cardiopulmonary rehabilitation on pulmonary arterial hypertension: A prospective, randomized study. <i>Turkish Journal of Physical Medicine and Rehabilitation</i> , 2019, 65, 278-286.	1.1	6
31	Differences in Baseline Characteristics and Access to Treatment of Newly Diagnosed Patients With IPF in the EMPIRE Countries. <i>Frontiers in Medicine</i> , 2021, 8, 729203.	2.6	5
32	Doppler Echocardiographic Index of Global Right Ventricular Function. <i>Circulation</i> , 2000, 101, E117.	1.6	4
33	RISE-IIP: Riociguat for the treatment of pulmonary hypertension associated with idiopathic interstitial pneumonia. , 2017, , .		4
34	Right ventricular function in patients with pulmonary arterial hypertension associated with congenital heart disease with repaired and unrepaired defects; correlation of speckle tracking, conventional echocardiography and clinical parameters. <i>Anatolian Journal of Cardiology</i> , 2020, 23, 277-287.	0.9	3
35	Development and Validation of a Clinical Diagnostic Scoring System for the Diagnosis of IPF. <i>Annals of the American Thoracic Society</i> , 2021, 18, 1803-1810.	3.2	2
36	Does timeliness of diagnosis influence survival and treatment response in idiopathic pulmonary fibrosis? Real- world results from the EMPIRE registry. , 2017, , .		2

#	ARTICLE	IF	CITATIONS
37	Real world idiopathic pulmonary fibrosis in the EMPIRE registry. , 2018, , .		2
38	Sequencing of mutations in the serine/threonine kinase domain of the bone morphogenetic protein receptor type 2 gene causing pulmonary arterial hypertension. Anatolian Journal of Cardiology, 2015, 16, 491-496.	0.9	2
39	Does body mass index have prognostic significance for patients with idiopathic pulmonary fibrosis?. , 2018, , .		2
40	Long-term overall survival and progression-free survival in idiopathic pulmonary fibrosis treated by pirfenidone or nintedanib or their switch. Real world data from the EMPIRE registry. , 2019, , .		2
41	Differences in baseline characteristics of newly diagnosed IPF patents in the EMPIRE countries. , 2018, , .		1
42	Bleeding risk in IPF patients treated with different anticoagulants:Real world data from the European MultiPartner IPF Registry (EMPIRE). , 2018, , .		1
43	Differences between ANCA positive and negative lung fibrosis cases without vasculitis. , 2019, , .		1
44	Temporal progression of mediastinal lymphadenopathy in idiopathic pulmonary fibrosis. European Respiratory Journal, 2022, 59, 2200024.	6.7	1
45	Erratum to "High dose rate endobronchial brachytherapy in the management of lung cancer: Response and toxicity evaluation in 158 patients" [Lung Cancer 62 (2008) 326-333]. Lung Cancer, 2009, 65, 128.	2.0	0
46	Intercostal Artery - Pulmonary Artery Arterio-Arteriolar Fistula: A Case Report. Chest, 2016, 150, 1205A.	0.8	0
47	Pulmonary Hypertension in Interstitial Lung Disease: Ege University Experience. Chest, 2016, 150, 1178A.	0.8	0
48	Variation in mortality from pulmonary hypertension by aetiology. , 2015, , .		0
49	Sarcoidosis Presenting with Membranous Nephropathy in a Patient with Hypertensive Nephropathy: Case Report. Turkish Nephrology, Dialysis and Transplantation Journal, 2015, 24, .	0.0	0
50	Variation in mortality from interstitial lung disease by diagnosis. , 2015, , .		0
51	Survival in CVD-ILD at Ege University Hospital. , 2016, , .		0
52	Neoplasia in patients with ILD; shortened survival. , 2016, , .		0
53	Prevalence of Latent Infection with Mycobacterium Tuberculosis in Interstitial Lung Diseases Using Interferon Gamma Release Assay. , 2017, , .		0
54	Analysis of comorbid conditions in 1210 IPF patients from the EMPIRE registry. , 2017, , .		0

#	ARTICLE	IF	CITATIONS
55	Comorbid conditions in IPF patients; their frequencies and impacts on survival. , 2018, , .		0
56	Does body mass index influence survival of patients with idiopathic pulmonary fibrosis?. , 2018, , .		0
57	Correlation of response to antifibrotic treatment with adverse events to antifibrotic drugs in IPF patients from the real-world EMPIRE registry. , 2020, , .		0
58	The effect of metformin on clinically relevant outcomes in 3,144 IPF patients from the EMPIRE registry. , 2020, , .		0